Saturday, 24 October 2020 22:00–22:50: POSTER DISCUSSION SESSION: Cancer Therapeutics: Preclinical Modeling and Patient Stratification| Volume 138, SUPPLEMENT 2, S18, October 01, 2020

Prospective validation of single mouse testing (SMT) by the pediatric preclinical testing consortium (PPTC)

      Background: The Research to Accelerate Cures and Equity for Children Act (RACE for Children Act) requires the FDA to develop a list of molecular targets of new drugs and biologics in development that are determined to be substantially relevant to the growth and progression of pediatric cancer, and that may trigger the requirement for pediatric investigations. This will require approaches to preclinical testing that incorporate models that accurately represent the genetic/epigenetic heterogeneity of pediatric cancers.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect